Safinamide (INN; brand name Xadago, former developmental code name EMD-1195686) is a drug indicated for the treatment of Parkinson's disease with multiple methods of action. In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011. The compound was originally discovered at Farmitalia-Carlo Erba, first published in 1998 and developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006. In October 2011 Merck-Serono announced that they would give all rights to develop the compound back to Newron.

CAS：133865-89-1
中文别名：(S)-2-[[4-[(3-氟苯甲基)氧]苯甲基]氨基]丙酰胺;
英文别名：(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide;(S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide;(2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide;Safinamide;
分子式：C17H19FN2O2
分子量：302.343
精确质量：302.143
Psa：64.35
Logp：3.4593

UNII：90ENL74SIG

密度：1.189 g/cm3
沸点：476.7ºC at 760 mmHg
折射率：1.569
蒸汽压：2.98E-09mmHg at 25°C